Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2018
At a glance
- Drugs Perampanel (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 01 Jul 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2022.
- 30 Jun 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2022.
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.